At the luncheon seminar of the 24th Annual Meeting of the Japanese Society for Regenerative Medicine, held from March 20 to 22, we will present the joint research results of Astellas Pharma Inc. and Epistra.
The seminar will introduce the outcomes of a stem cell culture condition optimization project combining the automated experiment robot “Mahoro” and our AI “Epistra Accelerate.”
Key achievements through the use of AI include:
- Significant improvement in differentiation efficiency compared to conventional methods
- Simultaneous achievement of “QbD” (design space) alongside condition optimization
Seminar Details
- Venue: Pacifico Yokohama North 4F G416+G417
- Chair: Dr. Yoji Sato (National Institute of Health Sciences)
Related Articles
- Epistra Contributes Article on "AI-Robot-Driven Drug Development" to Pharmacia, Journal of the Pharmaceutical Society of JapanEpistra CTO Taku Tsuzuki and CEO Yosuke Ozawa contributed an article on AI-robot-driven drug development to Pharmacia, Vol. 62 No. 7, published by the Pharmaceutical Society of Japan.
- Cell Culture Optimization Software 'CellTune Ver.2' Launches GloballyEpistra Inc. announces the global launch of 'CellTune Ver.2,' the updated version of the co-developed cell culture optimization software with Shimadzu Corporation, on June 29, 2026. The new version introduces cloud-based subscription delivery and overseas expansion of custom media manufacturing services.
- Speaking Engagement: CEO Yosuke Ozawa Presented at the 10th Shonan iPark Regenerative Medicine SeminarOn June 3, 2026, Epistra Inc. CEO Yosuke Ozawa presented at the 10th Shonan iPark Regenerative Medicine Seminar, sharing implementation case studies and future prospects for AI and mathematical optimization in regenerative medicine process development.